Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 1642
interventional 1475
Observational 160
Registry 7

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 856
Drug|Other 119
Biological 89
Biological|Drug 53
Drug|Procedure 43
Biological|Drug|Other 32
Drug|placebo 29
Other 27
Drug|Procedure|Radiation 24
Biological|Drug|Procedure|Radiation 20
Drug|Other|Procedure|Radiation 19
Biological|Drug|Other|Procedure|Radiation 17
Procedure 17
Biological|Drug|Procedure 15
Drug|Other|Procedure 13
Biological|Other 11
Behavioral 8
Biological|Drug|Other|Procedure 8
Device|Drug|Procedure 7
Drug|Genetic|Other 6
Biological|Drug|Radiation 5
Combination Product 5
Drug|Radiation 4
Other|Procedure 4
Biological|Device|Drug 3
Device 3
Genetic 3
Behavioral|Other 2
Biological|Drug|placebo 2
Biological|Other|placebo 2
Biological|Other|Procedure 2
Device|Drug 2
Drug|Genetic|Other|Procedure 2
Drug|placebo|Procedure 2
Behavioral|Drug 1
Behavioral|Other|Procedure 1
Biological|Combination Product 1
Biological|Combination Product|Drug 1
Biological|Device 1
Biological|Device|Drug|Procedure|Radiation 1
Biological|Device|Drug|Radiation 1
Biological|Drug|Genetic|Other|Procedure 1
Biological|Genetic 1
Biological|Genetic|Other|Procedure 1
Biological|placebo 1
Biological|Procedure 1
Device|Drug|Other|Procedure|Radiation 1
Device|Drug|Procedure|Radiation 1
Dietary Supplement|Drug 1
Drug|Genetic 1
Drug|Genetic|Other|Procedure|Radiation 1
Drug|Genetic|Procedure|Radiation 1
Drug|Other|placebo|Procedure 1
Drug|Other|Radiation 1
Procedure|Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 824
China 62
France 53
Germany 44
NA 34
United States|Canada 33
Japan 27
Italy 24
Spain 22
United Kingdom 18
Canada 17
Korea, Republic of 12
United States|Australia|Canada 9
Austria|Germany 8
Israel 7
United States|France 6
Australia 5
Belgium 5
Brazil 5
United States|Germany 5
United States|Germany|Italy 5
United States|Israel 5
Netherlands 4
Norway 4
Poland 4
Russian Federation 4
United States|Italy 4
Denmark 3
Hong Kong 3
Iran, Islamic Republic of 3
Singapore 3
United States|Korea, Republic of 3
Finland|Norway|Sweden 2
France|Germany 2
Germany|Netherlands 2
Germany|Switzerland 2
Japan|Korea, Republic of|Taiwan 2
Sweden 2
Switzerland 2
United States|Australia 2
United States|Australia|Canada|Netherlands|New Zealand|Puerto Rico|Switzerland 2
United States|Canada|France|Germany|Hungary|India|Italy|Poland|Singapore|United Kingdom 2
United States|Canada|France|Germany|Italy|Spain 2
United States|Germany|Spain 2
United States|Spain 2
Algeria|Argentina|Australia|Brazil|Canada|Egypt|India|Israel|Lebanon|Malaysia|Mexico|Oman|Russian Federation|Saudi Arabia|South Africa|Taiwan|Thailand|Tunisia|United Arab Emirates 1
Argentina|Australia|Brazil|Canada|France|Spain 1
Argentina|Belgium|Canada|Denmark|Finland|France|Italy|Netherlands|Norway|Sweden 1
Argentina|Brazil|China|Colombia|Germany|Guatemala|India|Mexico|Panama|Poland|Russian Federation|Venezuela 1
Australia|Belgium|France|Germany|Italy|Korea, Republic of|Netherlands|Singapore|Spain|Sweden|United Kingdom 1
Australia|Brazil|France|Israel|Italy|Russian Federation|Spain|Switzerland|Turkey 1
Australia|Canada|Estonia|Finland|Germany|Greece|New Zealand|Norway|Sweden 1
Australia|France 1
Australia|France|Spain|United Kingdom 1
Australia|United States|Austria|Belgium|Bulgaria|Canada|Czechia|Denmark|Finland|France|Germany|Hungary|Italy|Japan|Korea, Republic of|Netherlands|Poland|Romania|Russian Federation|Serbia|Spain|Sweden|Taiwan|United Kingdom 1
Australia|United States|Canada|Germany|Israel|Italy|New Zealand|Poland|Romania|Russian Federation|Spain|Sweden|Ukraine 1
Austria 1
Austria|Belgium|Bulgaria|Croatia|Czechia|Denmark|Finland|France|Germany|Greece|Hungary|Italy|Norway|Poland|Portugal|Romania|Serbia|Slovakia|Slovenia|Spain|Sweden|United Kingdom 1
Austria|Belgium|Canada|France|Germany|Italy|Norway 1
Austria|Belgium|Croatia|France|Germany|Italy|Netherlands 1
Austria|Belgium|Croatia|France|Italy|Netherlands 1
Austria|Canada|Finland|Norway|Russian Federation|Sweden 1
Belgium|Denmark|France|Germany|Italy|Netherlands|Spain|Sweden|United Kingdom 1
Belgium|France|Germany|Italy|Spain 1
Belgium|Germany 1
Belgium|Germany|United Kingdom 1
Belgium|Switzerland 1
Bulgaria|Canada|India|Russian Federation|Slovakia|South Africa|Spain 1
Bulgaria|Croatia|Czechia|Estonia|Finland|France|Greece|Hungary|Italy|Lithuania|Norway|Romania|Serbia|Slovakia|Spain|Sweden 1
Canada|France 1
Canada|France|Germany|Italy|Spain 1
China|Malaysia|Russian Federation|Singapore|Thailand 1
Colombia|Venezuela 1
Czechia|Denmark|Finland|France|Germany|Greece|Netherlands|Norway|Portugal|Sweden 1
Czechia|Germany|Switzerland 1
Czechia|United States|Argentina|Australia|Belgium|Brazil|Bulgaria|Canada|China|Croatia|France|Germany|Hong Kong|Hungary|Israel|Italy|Japan|Korea, Republic of|Poland|Portugal|Romania|Russian Federation|Serbia|Singapore|Spain|Taiwan|Ukraine|United Kingdom 1
Denmark|Finland|Norway|Sweden 1
Denmark|Germany|Netherlands 1
Denmark|United Kingdom 1
Egypt 1
Finland 1
Finland|Germany|Netherlands|Norway|Sweden 1
France|Germany|Italy 1
France|Germany|United Kingdom 1
France|Switzerland 1
France|United States|Australia|Austria|Belgium|Brazil|Canada|Czechia|Finland|Germany|Ireland|Israel|Italy|Korea, Republic of|Lithuania|Mexico|Poland|Portugal|Russian Federation|Spain|Taiwan|Turkey|United Kingdom 1
Germany|Austria 1
Germany|United States|Australia|Austria|Belgium|Canada|Denmark|Finland|France|Hong Kong|Italy|Korea, Republic of|Netherlands|New Zealand|Norway|Poland|Singapore|Spain|Sweden|Switzerland|Taiwan|United Kingdom 1
Hong Kong|Japan|Korea, Republic of|Russian Federation|Taiwan|Thailand|Vietnam 1
India 1
India|Korea, Republic of|Thailand 1
Indonesia|Korea, Republic of|Philippines|Thailand 1
Ireland|Italy|United Kingdom 1
Israel|Italy 1
Japan|Korea, Republic of 1
Jordan|Lebanon|Saudi Arabia|Tunisia 1
Korea, Republic of|Turkey|Ukraine 1
Lebanon 1
Malaysia 1
Mexico 1
Peru|United States|Poland|Argentina|Australia|Austria|Belgium|Brazil|Chile|China|Colombia|Czech Republic|Denmark|France|Germany|Greece|Hungary|India|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Russian Federation|Singapore|Spain|Turkey 1
Portugal|Spain 1
Spain|United States|Australia 1
Thailand 1
Turkey 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Czechia|France|Germany|Israel|Italy|Japan|Norway|Poland|Portugal|Spain|Switzerland|Taiwan|Turkey 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|China|Denmark|Estonia|Finland|France|Germany|Hungary|Ireland|Israel|Italy|Korea, Republic of|Norway|Peru|Philippines|Poland|Puerto Rico|Russian Federation|Singapore|South Africa|Spain|Sweden|Switzerland|Taiwan|Thailand|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Czech Republic|Denmark|Finland|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Korea, Republic of|Netherlands|Norway|Peru|Philippines|Poland|Russian Federation|Singapore|South Africa|Spain|Sweden|Switzerland|Taiwan|Thailand|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Czech Republic|Denmark|Finland|France|Germany|Hungary|Ireland|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Norway|Peru|Philippines|Poland|Russian Federation|Singapore|South Africa|Spain|Sweden|Switzerland|Taiwan|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Denmark|Finland|France|Germany|Israel|Italy|Korea, Republic of|Netherlands|Norway|Peru|Sweden|Switzerland|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|Chile|China|Colombia|Finland|France|Hong Kong|Hungary|India|Italy|Japan|Korea, Republic of|Latvia|Netherlands|Peru|Poland|Russian Federation|Singapore|South Africa|Spain|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|China|Czechia|France|Germany|Greece|Hungary|Ireland|Japan|Korea, Republic of|Mexico|New Zealand|Norway|Puerto Rico|Russian Federation|South Africa|Spain|Taiwan|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|Denmark|Finland|France|Germany|Israel|Italy|Korea, Republic of|Netherlands|Norway|Peru|Philippines|Singapore|Sweden|Switzerland|Taiwan|Thailand|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|Finland|France|Germany|Hungary|Ireland|Israel|Italy|Korea, Republic of|Norway|Peru|Poland|Russian Federation|South Africa|Spain|Sweden|Switzerland|Thailand|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|France|Germany|Greece|Israel|Japan|Korea, Republic of|Mexico|Poland|Russian Federation|Singapore|Spain|Tunisia|United Kingdom 1
United States|Argentina|Australia|Brazil|Bulgaria|Canada|Czechia|France|Germany|Hungary|Israel|Italy|Japan|Korea, Republic of|Lebanon|Mexico|Netherlands|Romania|Russian Federation|Saudi Arabia|Serbia|Spain|Switzerland|Turkey|United Kingdom 1
United States|Argentina|Australia|Canada|Chile|Czechia|Denmark|France|Germany|Hong Kong|Italy|Korea, Republic of|Poland|Portugal|Russian Federation|Singapore|Spain|Sweden|Switzerland|Taiwan|United Kingdom 1
United States|Argentina|Austria|Belgium|Brazil|Canada|China|Czechia|France|Hungary|Italy|Korea, Republic of|Poland|Spain|Thailand 1
United States|Argentina|Austria|Belgium|Brazil|Canada|Colombia|Czechia|Denmark|Egypt|Finland|France|Germany|Hong Kong|Hungary|Italy|Japan|Korea, Republic of|Malaysia|Mexico|Netherlands|Norway|Poland|Portugal|Russian Federation|Singapore|Slovakia|South Africa|Spain|Sweden|Switzerland|Taiwan|Thailand|Turkey|United Kingdom|Venezuela 1
United States|Argentina|Austria|Belgium|Brazil|Canada|Czechia|Finland|France|Germany|Greece|Hungary|India|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Norway|Poland|Portugal|Russian Federation|South Africa|Spain|Taiwan 1
United States|Argentina|Austria|Belgium|Bulgaria|Colombia|Denmark|France|Germany|Greece|Hungary|Ireland|Italy|Japan|Netherlands|Poland|Spain|Sweden|United Kingdom 1
United States|Argentina|Belgium|Brazil|Canada|Czechia|Germany|Greece|Hong Kong|Hungary|Ireland|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Puerto Rico|Russian Federation|Spain|Taiwan|Thailand 1
United States|Argentina|Korea, Republic of|Australia|Austria|Brazil|Czechia|France|Germany|Hungary|Italy|Poland|Romania|Spain|Taiwan|United Kingdom 1
United States|Australia|Austria|Belgium|Brazil|Canada|China|Czechia|Denmark|France|Germany|Italy|Korea, Republic of|Russian Federation|Spain|Taiwan|Turkey|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|China|Czechia|France|Germany|Hungary|Israel|Italy|Japan|Korea, Republic of|Mexico|Poland|Romania|Russian Federation|Spain|Sweden|Taiwan|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|China|Czechia|France|Germany|Israel|Italy|Korea, Republic of|Netherlands|Poland|Russian Federation|Spain|Taiwan|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Czechia|France|Germany|Hungary|Italy|Korea, Republic of|New Zealand|Poland|Spain|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Denmark|Finland|France|Germany|Ireland|Israel|Italy|Korea, Republic of|Netherlands|Norway|Peru|Singapore|South Africa|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Denmark|Finland|France|Germany|Israel|Italy|Korea, Republic of|Netherlands|Norway|Philippines|Singapore|Sweden|Switzerland|Taiwan|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Denmark|France|Germany|Italy|Netherlands|New Zealand|Norway|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Austria|Belgium|France|Germany|Korea, Republic of|Poland|Spain 1
United States|Australia|Austria|Brazil|Canada|China|Czechia|France|Germany|Israel|Italy|Spain|Japan|Korea, Republic of|Mexico|Netherlands|Poland|Russian Federation|Taiwan|United Kingdom 1
United States|Australia|Austria|Canada|Chile|Czechia|Denmark|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Poland|Portugal|Russian Federation|Spain|Taiwan|United Kingdom 1
United States|Australia|Belgium|Brazil|Canada|China|Czechia|France|Germany|Greece|Israel|Italy|Japan|Korea, Republic of|Mexico|Poland|Russian Federation|Spain|Turkey|United Kingdom 1
United States|Australia|Belgium|Canada|Croatia|Czechia|France|Germany|Hong Kong|Hungary|Italy|Korea, Republic of|Netherlands|Poland|Serbia|Singapore|Spain|Taiwan|United Kingdom 1
United States|Australia|Belgium|Canada|Czechia|Denmark|Finland|France|Germany|Hungary|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Norway|Poland|Singapore|Slovakia|South Africa|Spain|Sweden|Taiwan|Thailand|Ukraine|United Kingdom 1
United States|Australia|Belgium|Canada|France|Germany|Ireland|Italy|Norway|Poland|Romania|Spain|United Kingdom 1
United States|Australia|Belgium|Canada|France|Germany|Italy|Japan|Korea, Republic of|Poland|Spain|Taiwan|United Kingdom 1
United States|Australia|Belgium|France|Germany|Israel|Korea, Republic of|Poland|Russian Federation|Spain|Sweden|Taiwan|Turkey|United Kingdom 1
United States|Australia|Belgium|France|Germany|Italy|Korea, Republic of|Peru|Spain|Switzerland|Turkey|United Kingdom 1
United States|Australia|Brazil|Canada|China|Czechia|France|Germany|Greece|Hungary|Italy|Japan|Korea, Republic of|Puerto Rico|Russian Federation|Spain|Taiwan|Turkey|United Kingdom 1
United States|Australia|Brazil|Canada|China|Czechia|France|Germany|Israel|Italy|Japan|Korea, Republic of|Russian Federation|Spain|Switzerland|Taiwan|United Kingdom 1
United States|Australia|Canada|Croatia|Czechia|France|Hungary|Mexico|Poland|Romania|Russian Federation|Serbia|Spain|Taiwan|United Kingdom 1
United States|Australia|Canada|Denmark|Estonia|Finland|France|Germany|Israel|New Zealand|Sweden|United Kingdom 1
United States|Australia|Canada|France|Germany|Italy|Korea, Republic of|Netherlands|Portugal|Spain|Switzerland|United Kingdom 1
United States|Australia|Canada|France|Germany|Italy|Korea, Republic of|Spain|United Kingdom 1
United States|Australia|Canada|France|Germany|Italy|Spain 1
United States|Australia|Canada|France|Italy|Korea, Republic of|United Kingdom 1
United States|Australia|Canada|Germany|Japan 1
United States|Australia|Canada|Ireland|Italy|Netherlands|Spain 1
United States|Australia|Canada|New Zealand|Puerto Rico 1
United States|Australia|Canada|New Zealand|Puerto Rico|Saudi Arabia 1
United States|Australia|Canada|New Zealand|Puerto Rico|Switzerland 1
United States|Australia|Canada|Puerto Rico|Switzerland 1
United States|Australia|Finland|France|Germany|Netherlands|Spain|United Kingdom 1
United States|Australia|Finland|Italy|Singapore|Spain|Switzerland 1
United States|Australia|France 1
United States|Australia|France|Germany 1
United States|Australia|France|Germany|Italy|Japan|Korea, Republic of|Netherlands|Singapore|Spain 1
United States|Australia|France|Germany|Italy|Japan|Romania|Spain|United Kingdom 1
United States|Australia|France|Italy|Spain 1
United States|Australia|France|Spain 1
United States|Australia|Germany 1
United States|Australia|Germany|Italy 1
United States|Australia|Ireland 1
United States|Australia|Singapore 1
United States|Austria|Belgium|Canada|France|Germany|Hungary|Italy|Korea, Republic of|Spain|Sweden|Switzerland|Thailand|United Kingdom 1
United States|Austria|Belgium|Canada|France|Germany|Italy|Netherlands|Poland|Portugal|Spain|United Kingdom 1
United States|Austria|Belgium|France|Germany|Hungary|Italy|Poland|Spain|Sweden|Switzerland|United Kingdom 1
United States|Austria|France|Germany|Italy|Norway|Spain|Sweden 1
United States|Belgium 1
United States|Belgium|Bulgaria|Canada|Czechia|France|Germany|Ireland|Israel|Italy|Netherlands|Spain 1
United States|Belgium|Canada|Denmark|France|Germany|Hungary|Italy|Japan|Korea, Republic of|Poland|Spain|Sweden|Ukraine|United Kingdom 1
United States|Belgium|Canada|France|Germany|Greece|Netherlands|Poland|Serbia|United Kingdom 1
United States|Belgium|Canada|France|Germany|Israel|Italy|Japan|Korea, Republic of|Poland|Spain|Taiwan|Turkey|United Kingdom 1
United States|Belgium|Canada|France|Germany|United Kingdom 1
United States|Belgium|Czechia|France|Hungary|India|Italy|Korea, Republic of|Romania|Spain|United Kingdom 1
United States|Belgium|Denmark|France|Israel|Italy|Netherlands|Spain|Sweden 1
United States|Belgium|France|Italy|Netherlands 1
United States|Brazil|Canada|Czechia|Denmark|France|Germany|Greece|Hungary|Israel|Italy|Japan|Korea, Republic of|Poland|Portugal|Romania|Serbia|Spain|Sweden|Taiwan|United Kingdom 1
United States|Brazil|Denmark|France|Germany|Hong Kong|Italy|Korea, Republic of|Puerto Rico|Taiwan|United Kingdom 1
United States|Brazil|France|Israel|Italy|Netherlands|Portugal|Singapore|Spain|United Kingdom 1
United States|Brazil|France|Italy|Korea, Republic of|Netherlands|Russian Federation|United Kingdom 1
United States|Canada|Australia|Belgium|Denmark|France|Germany|Greece|Italy|Japan|Korea, Republic of|New Zealand|Poland|Spain|Taiwan|United Kingdom 1
United States|Canada|Denmark|France|Germany|Israel|Italy|Netherlands|Poland|Spain|United Kingdom 1
United States|Canada|France 1
United States|Canada|France|Germany|Italy 1
United States|Canada|France|Germany|Italy|Netherlands|Poland|Spain|United Kingdom 1
United States|Canada|France|Italy 1
United States|Canada|France|Italy|Norway|Spain|United Kingdom 1
United States|Canada|France|Italy|United Kingdom 1
United States|Canada|France|Poland 1
United States|Canada|France|Spain 1
United States|Canada|Germany|Italy|Poland|Spain 1
United States|Canada|Germany|Poland|Switzerland 1
United States|Canada|Netherlands 1
United States|Canada|New Zealand 1
United States|Canada|Puerto Rico 1
United States|Denmark 1
United States|Denmark|Germany 1
United States|France|Australia|Austria|Belgium|Brazil|Canada|China|Croatia|Czechia|Denmark|Finland|Germany|Hungary|Israel|Italy|Japan|Korea, Republic of|Norway|Poland|Portugal|Puerto Rico|Russian Federation|South Africa|Spain|Sweden|Taiwan|Turkey|Ukraine 1
United States|France|Germany 1
United States|France|Germany|Italy|Korea, Republic of 1
United States|France|Germany|Italy|Switzerland|United Kingdom 1
United States|France|Germany|Italy|United Kingdom 1
United States|France|Germany|Norway 1
United States|France|Germany|Spain 1
United States|France|Hungary|Italy|Japan|Korea, Republic of|Malaysia|Netherlands|Russian Federation|Spain|Thailand|Turkey|United Kingdom 1
United States|France|Israel|Japan|United Kingdom 1
United States|France|Italy|Netherlands 1
United States|France|Italy|Spain 1
United States|France|Italy|United Kingdom 1
United States|France|United Kingdom 1
United States|Georgia 1
United States|Germany|Ireland|Israel 1
United States|Germany|Israel 1
United States|Germany|Italy|Spain 1
United States|Germany|Netherlands 1
United States|Germany|United Kingdom 1
United States|Hungary|Israel|Italy|Spain 1
United States|India|Israel 1
United States|Israel|Peru 1
United States|New Zealand 1
United States|Puerto Rico 1
United States|Puerto Rico|South Africa 1
United States|Singapore 1
United States|Spain|United Kingdom 1
United States|Switzerland 1
United States|United Kingdom 1

Sites per Study

Site_count Study_Count
1 759
2 96
3 65
4 36
5 50
6 33
7 27
8 27
9 28
10 22
11 18
12 15
13 15
14 8
15 9
16 7
17 12
18 9
19 10
20 8
21 14
22 9
23 7
24 5
25 6
26 7
27 7
28 3
29 3
30 4
31 1
32 4
33 2
34 4
35 2
36 3
38 4
40 2
42 2
43 3
44 1
45 5
46 2
47 1
49 1
50 4
51 2
52 2
53 4
54 3
55 1
56 1
57 1
59 1
60 2
61 2
62 4
65 4
66 3
69 1
70 1
71 1
72 1
73 3
76 1
78 2
81 3
82 1
84 1
85 3
86 1
87 1
88 1
90 1
92 1
95 1
96 1
97 2
98 1
99 3
100 1
101 1
108 1
109 2
112 2
118 2
119 1
120 1
122 1
124 1
127 1
128 1
130 1
131 2
132 1
135 1
137 1
139 1
144 1
148 1
149 1
151 1
153 1
163 1
169 1
171 1
172 1
176 1
177 1
178 1
179 1
185 1
192 1
198 1
201 1
218 1
220 2
225 1
233 1
234 1
235 1
241 1
242 1
244 1
269 1
341 2
447 1
454 1

Phase

Phase Study_Count
Phase 2 550
Phase 1 392
Phase 1/Phase 2 226
Phase 3 158
N/A 79
Phase 4 32
Phase 2/Phase 3 28
Early Phase 1 10

Number of Arms

Number_of_Arms Count_of_Studies
1 784
2 358
3 81
4 44
5 13
6 17
7 7
9 4
10 1
11 1
12 1
13 1
16 1
NA 162

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 6.00 2.00000 2.00000 2.00000 2.00000 9.00 6.0000 18.00
1st Qu. 12.50 25.50000 18.00000 30.50000 32.00000 49.50 200.7500 61.75
Median 20.00 50.00000 30.00000 45.00000 55.00000 119.00 360.0000 107.00
Mean 24.60 90.82278 39.70157 76.76682 87.14367 322.75 434.8182 146.50
3rd Qu. 30.75 111.00000 50.00000 79.00000 106.00000 265.25 538.2500 165.25
Max. 55.00 506.00000 330.00000 2000.00000 862.00000 2000.00 3500.0000 600.00

Trial Group Type

group_type Group_Count
Experimental 1887
Active Comparator 213
NA 162
Other 67
Placebo Comparator 34
No Intervention 30
Sham Comparator 2

Intervention Model

intervention_model Study_Count
Single Group Assignment 916
Parallel Assignment 412
NA 76
Sequential Assignment 51
Crossover Assignment 13
Factorial Assignment 7

Primary Purpose

primary_purpose Study_Count
Treatment 1359
Supportive Care 44
Prevention 26
Other 14
NA 11
Diagnostic 8
Basic Science 6
Health Services Research 6
Screening 1

Observational Studies

Studies by Country

Country Study_Count
United States 56
NA 19
France 18
Italy 12
Spain 6
China 5
Egypt 4
Germany 3
United Kingdom 3
Belgium 2
Brazil 2
Canada 2
Israel 2
Japan 2
United States|Canada 2
Australia 1
Austria 1
Austria|Croatia 1
Austria|Germany 1
Belgium|Croatia|France|Italy|North Macedonia|Slovakia|Slovenia|Turkey 1
Canada|Korea, Republic of 1
Denmark 1
France|Germany|Italy|Spain 1
Germany|Hungary|Denmark|Finland|Israel|Poland|Russian Federation|Saudi Arabia|United Kingdom 1
Ireland|United Kingdom 1
Jordan 1
Korea, Republic of 1
Mexico 1
Russian Federation 1
Taiwan 1
Turkey 1
United States|Australia|Canada|New Zealand|Puerto Rico|Switzerland 1
United States|Austria|Belgium|France|Germany|Greece|Iraq|Italy|Netherlands|Taiwan 1
United States|Austria|Brazil|China|Germany|Iraq|Italy|Malaysia|Netherlands 1
United States|France|Germany|Italy|Netherlands|Puerto Rico|Russian Federation|Spain 1
United States|Netherlands 1
United States|Puerto Rico 1

Sites per Study

Site_count Study_Count
1 102
2 8
3 5
6 1
7 4
8 1
10 2
12 1
14 2
15 2
16 1
17 2
19 3
20 1
25 1
26 1
32 2
33 2
37 2
38 1
39 1
40 1
42 1
46 2
49 1
52 1
56 1
66 2
70 1
77 1
144 1
192 1
214 1
225 1

Enrollment Metrics

Measure Observational
Min 1.000
1st Qu 60.000
Median 150.000
Mean 1129.535
3rd Qu 330.000
Max 99999.000

Observation Model

observational_model Study_Count
Cohort 80
Case-Only 47
Other 12
Case-Control 10
NA 6
Case Control 4
Ecologic or Community 1

Time Perspective

time_perspective Study_Count
Prospective 91
Retrospective 47
Cross-Sectional 12
Other 5
NA 5

Registries

Studies by Country

Country Study_Count
United States 3
Brazil 1
Canada 1
Germany 1
Hong Kong 1

Sites per Study

Site_count Study_Count
1 5
6 1
7 1

Enrollment Metrics

Measure Registries
Min 100.000
1st Qu 165.000
Median 547.000
Mean 1282.429
3rd Qu 1500.000
Max 5000.000

Registry Model

observational_model Study_Count
Cohort 3
Other 3
Case-Only 1

Time Perspective

time_perspective Study_Count
Prospective 4
Other 2
Cross-Sectional 1

Follow-up

target_duration Study_Count
1 Year 3
5 Years 3
10 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03233074 Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy Donors https://ClinicalTrials.gov/show/NCT03233074 Recruiting Institut de Cancérologie de la Loire 2020-09-30
NCT04454580 Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy https://ClinicalTrials.gov/show/NCT04454580 Recruiting Ospedale Maggiore Di Trieste 2020-07-23
NCT03311815 Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia. https://ClinicalTrials.gov/show/NCT03311815 Recruiting PETHEMA Foundation 2020-09-30
NCT03284593 Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition https://ClinicalTrials.gov/show/NCT03284593 Active, not recruiting University Hospital, Toulouse 2030-12-31
NCT03262974 Effect of Pharmacogenetics on Imatinib Plasma Level and Response https://ClinicalTrials.gov/show/NCT03262974 Active, not recruiting Assiut University 2021-05-31
NCT03075969 Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia https://ClinicalTrials.gov/show/NCT03075969 Active, not recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2019-03-16
NCT03047083 Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review https://ClinicalTrials.gov/show/NCT03047083 Completed Astellas Pharma Inc 2017-05-19
NCT03045120 Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States https://ClinicalTrials.gov/show/NCT03045120 Recruiting Bristol-Myers Squibb 2021-01-31
NCT02977312 Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan https://ClinicalTrials.gov/show/NCT02977312 Completed Hikma Pharmaceuticals LLC 2015-02-28
NCT02927106 Beat AML Core Study https://ClinicalTrials.gov/show/NCT02927106 Recruiting University of Florida 2024-02-15
NCT02921815 A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment https://ClinicalTrials.gov/show/NCT02921815 Active, not recruiting Celgene 2020-06-19
NCT02900430 Invasives Aspergillosis in Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT02900430 Completed University Hospital, Brest 2015-12-31
NCT02899767 Transfusion in Adult Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT02899767 Completed Hospices Civils de Lyon 2014-12-31
NCT02896829 Follow-up of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia https://ClinicalTrials.gov/show/NCT02896829 Completed University Hospital, Bordeaux 2019-04-30
NCT02895542 Preparatory Work to Assess Adherence to Oral Chemotherapy https://ClinicalTrials.gov/show/NCT02895542 Completed Wake Forest University Health Sciences 2017-04-28
NCT02891551 An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands https://ClinicalTrials.gov/show/NCT02891551 Completed Celgene 2016-06-30
NCT02869256 Regional Central Database Recording of Chronic Myeloid Leukemia https://ClinicalTrials.gov/show/NCT02869256 Recruiting Institut Bergonié 2024-01-31
NCT02844257 Transfusion Dependency at Diagnosis and Transfusion Intensity During Initial Chemotherapy Are Associated With Poorer Outcomes in Adult Acute Myeloid Leukaemia https://ClinicalTrials.gov/show/NCT02844257 Completed Hospices Civils de Lyon 2014-12-31
NCT02844218 Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT02844218 Completed Hospices Civils de Lyon 2014-12-31
NCT02845232 Economic Analysis of Blood Product Transfusions According to the Treatment of Acute Myeloid Leukaemia in the Elderly https://ClinicalTrials.gov/show/NCT02845232 Completed Hospices Civils de Lyon 2014-12-31
NCT02842229 A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms https://ClinicalTrials.gov/show/NCT02842229 Completed Celgene 2017-02-02
NCT02842112 Higher Percentage of CD34+ CD38- Cells Detected by Multiparameter Flow Cytometry From Leukapheresis Products Predicts Unsustained Complete Remission in Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT02842112 Completed Hospices Civils de Lyon 2013-12-31
NCT02774850 Home Away From Home - Medical Outcomes https://ClinicalTrials.gov/show/NCT02774850 Completed Children’s Hospital of Philadelphia 2019-07-26
NCT02777021 Home Away From Home - Quality of Life Surveys https://ClinicalTrials.gov/show/NCT02777021 Completed Children’s Hospital of Philadelphia 2019-07-18
NCT02767388 Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery https://ClinicalTrials.gov/show/NCT02767388 Completed University of Nebraska 2017-12-11
NCT02759822 Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias https://ClinicalTrials.gov/show/NCT02759822 Recruiting Instituto Nacional de Cancer, Brazil 2021-04-30
NCT02734823 Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor https://ClinicalTrials.gov/show/NCT02734823 Recruiting University of Southern California 2020-03-01
NCT02714790 Prognostic Role of Minimal Residual Disease in Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT02714790 Completed Azienda Ospedaliera Città della Salute e della Scienza di Torino 2015-06-30
NCT02667093 Samples From Leukemia Patients and Their Donors to Identify Specific Antigens https://ClinicalTrials.gov/show/NCT02667093 Active, not recruiting PersImmune, Inc 2020-12-31
NCT02662920 Investigating the Prevalence and Prognostic Importance of Polypharmacy in Adults Treated for Newly Diagnosed Acute Myelogenous Leukemia (AML) https://ClinicalTrials.gov/show/NCT02662920 Completed Wake Forest University Health Sciences 2014-04-30
NCT00559065 A Case-Cohort Study of Hematopoietic Malignancies and Related Disorders and Lung Cancer in Benzene-Exposed Workers in China https://ClinicalTrials.gov/show/NCT00559065 Completed National Institutes of Health Clinical Center (CC) NA
NCT01351545 A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) https://ClinicalTrials.gov/show/NCT01351545 Recruiting Center for International Blood and Marrow Transplant Research 2021-10-31
NCT02546375 A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands https://ClinicalTrials.gov/show/NCT02546375 Completed Pfizer 2017-01-16
NCT02527447 Biomarkers for Personalized Early Assessment of Response During Salvage Chemotherapy in People With Relapsed or Refractory Acute Myeloid Leukemia (PEARL15) https://ClinicalTrials.gov/show/NCT02527447 Completed National Institutes of Health Clinical Center (CC) 2018-05-10
NCT02501330 Safety And Efficacy Of Bosutinib https://ClinicalTrials.gov/show/NCT02501330 Recruiting Pfizer 2023-09-04
NCT02448095 Retrospective Evaluation of CML Patients in the National Compassionate Program https://ClinicalTrials.gov/show/NCT02448095 Recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2018-12-31
NCT02389972 Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study https://ClinicalTrials.gov/show/NCT02389972 Completed Bristol-Myers Squibb 2017-07-13
NCT02348957 Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib https://ClinicalTrials.gov/show/NCT02348957 Completed Onco Medical Consult GmbH 2019-03-31
NCT02338479 Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02338479 Active, not recruiting Center for International Blood and Marrow Transplant Research 2020-02-29
NCT02269267 The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study) https://ClinicalTrials.gov/show/NCT02269267 Active, not recruiting Medical College of Wisconsin 2020-09-30
NCT02222272 Effect of 2nd Gen TKI in CML https://ClinicalTrials.gov/show/NCT02222272 Completed European Group for Blood and Marrow Transplantation 2014-03-19
NCT02164903 LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia Patients https://ClinicalTrials.gov/show/NCT02164903 Active, not recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2017-01-25
NCT02161978 Vascular Dysfunction and Antiangiogenic Therapy https://ClinicalTrials.gov/show/NCT02161978 Completed University Hospital, Angers 2018-12-12
NCT01311258 Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT01311258 Recruiting University of Rochester 2020-08-31
NCT01298414 Biomarkers in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01298414 Completed Children’s Oncology Group 2016-05-31
NCT01290107 Biomarkers in Samples of Bone Marrow From Patients With Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01290107 Completed Children’s Oncology Group 2015-01-31
NCT01278069 PET-CT in AML for Detection of Extramedullary AML Manifestations https://ClinicalTrials.gov/show/NCT01278069 Completed Technische Universität Dresden 2013-09-30
NCT02016833 Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity https://ClinicalTrials.gov/show/NCT02016833 Completed PX Biosolutions 2014-06-30
NCT01999556 LCI-HEM-SPEC-001: Tissue Collection for Genetic Analysis of Acute Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT01999556 Recruiting Atrium Health 2021-09-30
NCT01976442 Use of Saline-Washed Platelet and Red Cell Transfusions in Adult Acute Leukemia https://ClinicalTrials.gov/show/NCT01976442 Completed University of Rochester 2016-11-30
NCT01929408 Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients https://ClinicalTrials.gov/show/NCT01929408 Completed Fred Hutchinson Cancer Research Center 2018-12-04
NCT04337138 A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World https://ClinicalTrials.gov/show/NCT04337138 Active, not recruiting Pfizer 2020-07-31
NCT01860456 TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study https://ClinicalTrials.gov/show/NCT01860456 Active, not recruiting University of Pisa 2021-05-31
NCT01805843 Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01805843 Completed Medical University of Graz 2015-06-30
NCT01752062 Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors https://ClinicalTrials.gov/show/NCT01752062 Recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2018-12-31
NCT01699217 Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase https://ClinicalTrials.gov/show/NCT01699217 Recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2019-11-30
NCT01642121 Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01642121 Completed Children’s Oncology Group 2016-05-31
NCT01608204 Busulfan Pharmacokinetic Analysis and GST Pharmacogenetic Profile in Adults Undergoing Hematological Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT01608204 Completed Rambam Health Care Campus 2011-12-31
NCT01595295 Registry on Hypomethylating Agents in Myeloid Neoplasms https://ClinicalTrials.gov/show/NCT01595295 Recruiting Arbeitsgemeinschaft medikamentoese Tumortherapie 2020-06-30
NCT01576185 Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01576185 Completed Children’s Oncology Group 2016-05-31
NCT01537159 MRI Assessment of Leukemia Response to Therapy https://ClinicalTrials.gov/show/NCT01537159 Completed OHSU Knight Cancer Institute 2018-12-31
NCT01511575 Studying Biomarker Expression in Samples From Patients With Down Syndrome and Acute Myeloid Leukemia or Other Transient Myeloproliferative Disorder https://ClinicalTrials.gov/show/NCT01511575 Completed Children’s Oncology Group 2016-05-31
NCT01507441 Studying DNA in Samples From Younger Patients With Down Syndrome and Acute Myeloid Leukemia Treated on COG-AAML0431 Clinical Trial https://ClinicalTrials.gov/show/NCT01507441 Completed Children’s Oncology Group 2016-05-31
NCT01490853 Follow-up of Ph+ Chronic Myleoid Leukemia Patients in Complete Cytogenetic Response With Interferon Based Therapy https://ClinicalTrials.gov/show/NCT01490853 Completed Università degli Studi di Brescia 2012-01-31
NCT01475110 Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib https://ClinicalTrials.gov/show/NCT01475110 Recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2018-12-31
NCT01437202 Pharmacogenomics Validation for Imatinib in Chronic Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01437202 Completed Asan Medical Center 2012-09-30
NCT01407757 Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531 https://ClinicalTrials.gov/show/NCT01407757 Completed Children’s Oncology Group 2016-05-31
NCT01394666 Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML) https://ClinicalTrials.gov/show/NCT01394666 Completed Bristol-Myers Squibb 2012-12-31
NCT01385787 MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01385787 Completed Center for International Blood and Marrow Transplant Research 2017-05-31
NCT01385150 Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01385150 Completed Eastern Cooperative Oncology Group 2012-02-03
NCT04446741 Molecular Diagnostic Platform for AML https://ClinicalTrials.gov/show/NCT04446741 Recruiting PETHEMA Foundation 2022-10-31
NCT04380441 Quality of Life Model for Older Patients With AML https://ClinicalTrials.gov/show/NCT04380441 Recruiting H. Lee Moffitt Cancer Center and Research Institute 2022-05-31
NCT04369287 Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT04369287 Recruiting Istituto Clinico Humanitas 2020-10-15
NCT04296214 Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT04296214 Recruiting Grupo Cooperativo de Hemopatías Malignas 2021-12-31
NCT04259372 Analysis of T Cell Metabolism in Acute Myeloid Leukemia Patients https://ClinicalTrials.gov/show/NCT04259372 Completed University of Freiburg 2019-12-31
NCT04253314 A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian Federation https://ClinicalTrials.gov/show/NCT04253314 Recruiting AbbVie 2023-10-17
NCT04150471 Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients https://ClinicalTrials.gov/show/NCT04150471 Recruiting Seoul St. Mary’s Hospital 2020-12-30
NCT04104035 Leukemic Stem Cell Detection for Chronic Myeloid Leukemia Patients With Major Molecular Response https://ClinicalTrials.gov/show/NCT04104035 Recruiting Ankara University 2021-01-31
NCT04089839 A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life Setting https://ClinicalTrials.gov/show/NCT04089839 Active, not recruiting Bristol-Myers Squibb 2020-10-31
NCT04048564 Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®) https://ClinicalTrials.gov/show/NCT04048564 Recruiting Incyte Corporation 2022-02-28
NCT04024241 Medium Dose of Cytarabine and Mitoxantrone https://ClinicalTrials.gov/show/NCT04024241 Recruiting Shenzhen People’s Hospital 2019-08-31
NCT03987958 A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study) https://ClinicalTrials.gov/show/NCT03987958 Recruiting AbbVie 2023-07-01
NCT03933852 Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose https://ClinicalTrials.gov/show/NCT03933852 Recruiting University of Jena 2022-12-31
NCT03921047 Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT03921047 Recruiting University of Southern California 2022-02-01
NCT03918655 MIF Involvement in AML https://ClinicalTrials.gov/show/NCT03918655 Recruiting Assistance Publique - Hôpitaux de Paris 2022-10-31
NCT03894852 SRSF2 Gene Mutation in Patients With t-MDS/AML https://ClinicalTrials.gov/show/NCT03894852 Completed Assiut University 2019-12-29
NCT03885076 Gamma Delta T Cells in AML https://ClinicalTrials.gov/show/NCT03885076 Recruiting Royal Marsden NHS Foundation Trust 2020-03-31
NCT03885830 Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients https://ClinicalTrials.gov/show/NCT03885830 Active, not recruiting UNC Lineberger Comprehensive Cancer Center 2020-12-31
NCT03881826 Investigation of the Gut Microbiota in Patients With Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT03881826 Recruiting Université Catholique de Louvain 2020-05-31
NCT03789981 Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT03789981 Recruiting Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori 2021-12-31
NCT03755856 Long-term Outcomes for Acute Myeloid Leukemia Patients https://ClinicalTrials.gov/show/NCT03755856 Recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2021-06-30
NCT03728699 Microbiota Changes in Acute Myeloid Leukemia Patients Undergoing Intensive Chemotherapy https://ClinicalTrials.gov/show/NCT03728699 Recruiting Masonic Cancer Center, University of Minnesota 2025-02-28
NCT03719183 Comparison of Diagnostic Yield Among M-FISH, FISH Probe Panel and Conventional Cytogenetic Analysis in AML https://ClinicalTrials.gov/show/NCT03719183 Enrolling by invitation Assiut University 2020-12-31
NCT03678454 Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium https://ClinicalTrials.gov/show/NCT03678454 Recruiting Incyte Corporation 2022-03-31
NCT03600558 Efficacy of FLAG Regimen for the Treatment of Patients With AML https://ClinicalTrials.gov/show/NCT03600558 Recruiting Tianjin Medical University General Hospital 2020-07-31
NCT03540654 Budget Impact Analysis of Discontinuing Tyrosin Kinase Inhibitors in Patients With Chronic Myeloid Leukemia Achieving a Complete Molecular Response by Using Probabilistic Markov Approach https://ClinicalTrials.gov/show/NCT03540654 Completed University Hospital, Bordeaux 2018-10-31
NCT03537560 Detection of IDH2 Mutations and Monitoring Molecular Residual Disease in Patients With AML https://ClinicalTrials.gov/show/NCT03537560 Enrolling by invitation Chang Gung Memorial Hospital 2019-09-30
NCT03526926 A Post-Marketing Observational Study of VYXEOSâ„¢ https://ClinicalTrials.gov/show/NCT03526926 Active, not recruiting Jazz Pharmaceuticals 2020-01-31
NCT03488862 Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients https://ClinicalTrials.gov/show/NCT03488862 Active, not recruiting UNC Lineberger Comprehensive Cancer Center 2020-10-01
NCT03481868 EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors https://ClinicalTrials.gov/show/NCT03481868 Recruiting University Hospital, Clermont-Ferrand 2021-02-10
NCT03454503 Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt https://ClinicalTrials.gov/show/NCT03454503 Active, not recruiting Hikma Pharmaceuticals LLC 2021-01-31
NCT03450512 Incidence of Neutropenic Enterocolitis Study in Acute Myeloid Leukemia Patients During Intensive Therapy https://ClinicalTrials.gov/show/NCT03450512 Recruiting Centre Hospitalier Universitaire, Amiens 2022-12-01
NCT03449745 Immune Checkpoint Receptors in AML-Leukemic Initiating Cells https://ClinicalTrials.gov/show/NCT03449745 Recruiting University Hospital, Bordeaux 2021-03-31
NCT03435341 Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain https://ClinicalTrials.gov/show/NCT03435341 Active, not recruiting Celgene 2020-02-28
NCT03433521 Observational Study of Spatio-Temporal Patterns of New Cases of Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT03433521 Completed Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz 2019-01-15
NCT03422731 Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy https://ClinicalTrials.gov/show/NCT03422731 Recruiting City of Hope Medical Center 2023-02-06
NCT03421626 Clinical Evaluation of a Test for Monitoring Patients Diagnosed With Chronic Myeloid Leukemia (CML) https://ClinicalTrials.gov/show/NCT03421626 Completed Cepheid 2018-08-20
NCT01252589 Patient Reported Outcomes in Chronic Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01252589 Completed Gruppo Italiano Malattie EMatologiche dell’Adulto 2013-09-30
NCT01252485 Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms, and Higher Risk Myelodysplastic Syndrome - The Biology and Outcome (BiO)-Project https://ClinicalTrials.gov/show/NCT01252485 Recruiting University of Ulm NA
NCT01247584 Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01247584 Completed Children’s Oncology Group 2016-05-31
NCT01244750 Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting https://ClinicalTrials.gov/show/NCT01244750 Active, not recruiting Bristol-Myers Squibb 2020-01-30
NCT01215487 A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib https://ClinicalTrials.gov/show/NCT01215487 Recruiting University of British Columbia 2022-01-31
NCT01203033 Prospective Pilot Study of Bone Marrow and Peripheral Blood Samples From AML Patients to Characterize the Biologic Heterogeneity of the Disease Using Single Cell Network Profiling (SCNP) https://ClinicalTrials.gov/show/NCT01203033 Completed West Virginia University 2012-09-30
NCT01199562 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01199562 Completed City of Hope Medical Center 2013-12-31
NCT01188278 Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey https://ClinicalTrials.gov/show/NCT01188278 Completed Bristol-Myers Squibb 2013-01-31
NCT01150058 Drug Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01150058 Completed Children’s Oncology Group 2012-11-30
NCT01146223 Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia https://ClinicalTrials.gov/show/NCT01146223 Completed Children’s Oncology Group 2011-06-30
NCT01144793 Biomarker To Evaluate Protein Profiles of Neutropenic Fever/Infection With Acute or Chronic Leukemias https://ClinicalTrials.gov/show/NCT01144793 Completed Stanford University 2008-06-30
NCT01146210 Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01146210 Completed Children’s Oncology Group 2016-05-31
NCT01139333 Blood and Tumor Tissue Samples From Young Patients With Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01139333 Completed Children’s Oncology Group 2016-05-31
NCT01076569 Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01076569 Completed Children’s Oncology Group 2016-05-31
NCT01059734 S9031-S9126-S9333-S9500-B Biomarker Expression in Patients With Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01059734 Completed Southwest Oncology Group 2012-06-30
NCT01057199 Studying Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01057199 Completed Children’s Oncology Group 2010-06-30
NCT01046305 Symptom Burden in Chronic Myeloid Leukemia (CML) https://ClinicalTrials.gov/show/NCT01046305 Active, not recruiting M.D. Anderson Cancer Center 2020-11-30
NCT01034839 High-dose Cytarabine and Survival in AML https://ClinicalTrials.gov/show/NCT01034839 Completed University of Sao Paulo General Hospital 2008-12-31
NCT01024127 Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01024127 Completed Children’s Oncology Group 2016-05-31
NCT01004965 Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720 https://ClinicalTrials.gov/show/NCT01004965 Active, not recruiting Alliance for Clinical Trials in Oncology 2011-01-31
NCT00969891 Study of Dosage Individualisation for the Treatment of Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT00969891 Completed University of Copenhagen NA
NCT00898755 Collecting and Storing Tissue From Young Patients With Cancer https://ClinicalTrials.gov/show/NCT00898755 Completed Children’s Oncology Group 2008-07-17
NCT00898092 Genetics Study of Tissue Collected From Patients With Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT00898092 Active, not recruiting Alliance for Clinical Trials in Oncology 2012-12-31
NCT00898456 Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT00898456 Active, not recruiting Alliance for Clinical Trials in Oncology 2100-01-31
NCT00898079 Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer https://ClinicalTrials.gov/show/NCT00898079 Completed Children’s Oncology Group 2018-06-30
NCT00896701 Relationship Between Natural Killer Cells’ Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2 https://ClinicalTrials.gov/show/NCT00896701 Completed Alliance for Clinical Trials in Oncology 2014-04-30
NCT00896129 Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy https://ClinicalTrials.gov/show/NCT00896129 Completed Gruppo Italiano Malattie EMatologiche dell’Adulto 2010-12-31
NCT03647215 CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey https://ClinicalTrials.gov/show/NCT03647215 Recruiting Incyte Corporation 2020-06-30
NCT04070807 Italian Observational Study of Patients With Acute Myeloid Leukemia Treated With Small Molecule Inhibiting BCL-2 https://ClinicalTrials.gov/show/NCT04070807 Recruiting Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori 2020-12-31
NCT00900224 Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT00900224 Active, not recruiting Alliance for Clinical Trials in Oncology 2015-12-31
NCT03350152 Treatment With Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) With Acute Myeloid Leukemia: A Single Institution Experience. https://ClinicalTrials.gov/show/NCT03350152 Completed Hospices Civils de Lyon 2014-06-01
NCT00816114 Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial https://ClinicalTrials.gov/show/NCT00816114 Recruiting M.D. Anderson Cancer Center 2020-06-30
NCT00806325 Clinical Factors Associated With the Development of Severe Sepsis in Patients Being Treated for Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT00806325 Completed Ohio State University 2010-02-28
NCT03165851 Efficacy Analysis of Comparison of CAMS(Chinese Academy of Medical Sciences)-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT03165851 Completed Institute of Hematology & Blood Diseases Hospital 2012-12-31
NCT02856204 Shotgun Sequencing in Diagnosing Febrile Neutropenia in Patients With Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT02856204 Completed Stanford University 2017-12-31
NCT02581917 Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT02581917 Recruiting Wake Forest University Health Sciences 2020-09-30
NCT01761890 Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib https://ClinicalTrials.gov/show/NCT01761890 Recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2018-12-31
NCT01688011 Connect® MDS/AML Disease Registry https://ClinicalTrials.gov/show/NCT01688011 Recruiting Celgene 2022-12-12
NCT03526666 Ascorbic Acid Levels in MDS, AML, and CMML Patients https://ClinicalTrials.gov/show/NCT03526666 Completed Van Andel Research Institute 2018-10-31
NCT00947830 Investigating Intracellular and Plasma Imatinib Levels in Chronic Myeloid Leukemia https://ClinicalTrials.gov/show/NCT00947830 Completed McMaster University 2012-04-30
NCT00632255 Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment https://ClinicalTrials.gov/show/NCT00632255 Completed Imperial College London 2009-05-31
NCT00525746 Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS) https://ClinicalTrials.gov/show/NCT00525746 Active, not recruiting M.D. Anderson Cancer Center 2025-03-31
NCT00513175 Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia https://ClinicalTrials.gov/show/NCT00513175 Completed University of California, San Francisco NA
NCT00502983 Molecular Epidemiology of Acute Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00502983 Active, not recruiting M.D. Anderson Cancer Center 2020-09-30
NCT00504920 Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients https://ClinicalTrials.gov/show/NCT00504920 Completed M.D. Anderson Cancer Center 2008-09-30
NCT00459524 Quality of Life of Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) https://ClinicalTrials.gov/show/NCT00459524 Completed M.D. Anderson Cancer Center 2009-03-31
NCT00429910 Natural History Study of Patients With Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00429910 Completed Dana-Farber Cancer Institute 2005-09-30
NCT00390715 Treatment of Acute Myeloblastic Leukemia in Younger Patients https://ClinicalTrials.gov/show/NCT00390715 Completed PETHEMA Foundation 2007-12-31
NCT00339664 Analyses of Human Samples Collected in Clinical Trials https://ClinicalTrials.gov/show/NCT00339664 Completed National Institutes of Health Clinical Center (CC) 2020-03-17
NCT00286845 Use of the MiCK Assay for Apoptosis in AML https://ClinicalTrials.gov/show/NCT00286845 Completed Pierian Biosciences NA
NCT00257647 Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML) https://ClinicalTrials.gov/show/NCT00257647 Completed Hadassah Medical Organization NA
NCT00003931 Diagnostic Study of Gene Alterations in Patients With Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT00003931 Completed Alliance for Clinical Trials in Oncology 2006-06-30
NCT00015587 Molecular Epidemiology of Childhood Leukemia (Aka The California Childhood Leukemia Study) https://ClinicalTrials.gov/show/NCT00015587 Completed National Institute of Environmental Health Sciences (NIEHS) 2016-07-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03023384 Feasibility Study of Intermediate Doses of ARA-C With Autologous SCT as Consolidation of Low/Intermediate-risk AML https://ClinicalTrials.gov/show/NCT03023384 Recruiting International Consortium on Acute Leukemias 2021-01-31
NCT02760238 Myeloproliferative Neoplasms (MPNs) Patient Registry https://ClinicalTrials.gov/show/NCT02760238 Recruiting University Health Network, Toronto 2025-10-31
NCT01890486 The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen https://ClinicalTrials.gov/show/NCT01890486 Recruiting Wake Forest University Health Sciences 2023-05-31
NCT04014764 Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy https://ClinicalTrials.gov/show/NCT04014764 Recruiting Notable Labs 2022-09-30
NCT03760237 Cardiovascular Function in Acute Leukemia https://ClinicalTrials.gov/show/NCT03760237 Enrolling by invitation Abramson Cancer Center of the University of Pennsylvania 2021-12-31
NCT03662724 Venetoclax Registry https://ClinicalTrials.gov/show/NCT03662724 Active, not recruiting Hannover Medical School 2021-11-01
NCT03625583 The Hong Kong CML Registry https://ClinicalTrials.gov/show/NCT03625583 Recruiting The University of Hong Kong 2023-03-31